Orchestra BioMed Inc.
OBIO | NASDAQ
$6.39
+$0.14 (+2.24%)
Sep 22, 2026, 11:26 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 33.48M | 2.64M | 2.76M | 3.53M | -782K | 5.7M |
Cost of Revenue | 190K | 204K | 186K | 322K | 199K | 145K |
Gross Profit | 33.29M | 2.43M | 2.57M | 3.21M | -981K | 5.56M |
Operating Income | -51.81M | -64.3M | -51.51M | -32.66M | -21.8M | -18.75M |
Interest Income | n/a | 3.36M | 3.85M | 50K | n/a | 331K |
Pretax Income | -52.7M | -61.02M | -49.12M | -33.61M | -23.01M | -21.36M |
Net Income | -52.7M | -61.02M | -49.12M | -33.61M | -23.01M | -21.36M |
Selling & General & Admin | 26.91M | 23.93M | 20.26M | 13.92M | 7.93M | 10.83M |
Research & Development | 58.19M | 42.8M | 33.82M | 21.95M | 12.89M | 13.48M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 85.1M | 66.74M | 54.08M | 35.87M | 20.82M | 24.31M |
Interest Expense | 1.15M | n/a | n/a | n/a | 927K | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 85.29M | 66.94M | 54.27M | 36.19M | 21.02M | 24.46M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 47.75M | 36.82M | 33.23M | 25.47M | 20.45M | 20.45M |
Shares Outstanding (Diluted) | 47.75M | 36.82M | 33.23M | 25.47M | 20.45M | 20.45M |
EPS (Basic) | -1.11 | -1.66 | -1.48 | -1.32 | -0.02 | -0.01 |
EPS (Diluted) | -1.11 | -1.66 | -1.48 | -1.32 | -0.02 | -0.01 |
EBITDA | -51.23M | -60.72M | -48.83M | -33.39M | -21.91M | -18.62M |
EBIT | -51.55M | -61.02M | -49.12M | -33.61M | -22.09M | -18.75M |
Depreciation & Amortization | 327K | 308K | 287K | 222K | 181K | 137K |
Add to Watchlist
Select watchlists to add or remove OBIO